- Home
- LFLY vs PALI Comparison
LFLY vs PALI Comparison
Compare LFLY & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFLY
- PALI
- Stock Information
- Founded
- LFLY 2010
- PALI 1996
- Country
- LFLY United States
- PALI United States
- Employees
- LFLY N/A
- PALI N/A
- Industry
- LFLY Computer Software: Prepackaged Software
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFLY Technology
- PALI Health Care
- Exchange
- LFLY Nasdaq
- PALI Nasdaq
- Market Cap
- LFLY 3.9M
- PALI 3.5M
- IPO Year
- LFLY N/A
- PALI N/A
- Fundamental
- Price
- LFLY $1.21
- PALI $1.85
- Analyst Decision
- LFLY Strong Buy
- PALI Strong Buy
- Analyst Count
- LFLY 2
- PALI 2
- Target Price
- LFLY $7.59
- PALI $23.00
- AVG Volume (30 Days)
- LFLY 32.7K
- PALI 3.7M
- Earning Date
- LFLY 11-07-2024
- PALI 11-12-2024
- Dividend Yield
- LFLY N/A
- PALI N/A
- EPS Growth
- LFLY N/A
- PALI N/A
- EPS
- LFLY N/A
- PALI N/A
- Revenue
- LFLY $35,868,000.00
- PALI N/A
- Revenue This Year
- LFLY N/A
- PALI N/A
- Revenue Next Year
- LFLY N/A
- PALI N/A
- P/E Ratio
- LFLY N/A
- PALI N/A
- Revenue Growth
- LFLY N/A
- PALI N/A
- 52 Week Low
- LFLY $1.20
- PALI $1.38
- 52 Week High
- LFLY $5.88
- PALI $22.35
- Technical
- Relative Strength Index (RSI)
- LFLY 34.88
- PALI 41.13
- Support Level
- LFLY $1.20
- PALI $1.59
- Resistance Level
- LFLY $1.35
- PALI $2.20
- Average True Range (ATR)
- LFLY 0.08
- PALI 0.38
- MACD
- LFLY 0.00
- PALI 0.02
- Stochastic Oscillator
- LFLY 16.92
- PALI 19.80
About LFLY Leafly Holdings Inc.
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.